Recent researches have reported that KIF20A was upregulated in esophageal squamous cell carcinoma (28), lung adenocarcinoma (29), prostate cancer (30), cervical cancer (31), colorectal cancer (32), non-small cell lung cancer (33), gastric cancer (34), bladder cancer (35), renal clear cell carcinoma (36), breast cancer (37), hepatocellular carcinoma (38), nasopharyngeal carcinoma (39), ovarian cancer (40), leukemia (25), glioma (41), and soft tissue sarcoma (42). Here, KIF20A is linked to urinary bladder carcinoma.